Seres Therapeutics Statistics
Share Statistics
Seres Therapeutics has 170.74M shares outstanding. The number of shares has increased by 13.06% in one year.
| Shares Outstanding | 170.74M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 12.05% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 124.81M |
| Failed to Deliver (FTD) Shares | 8.84K |
| FTD / Avg. Volume | 0.35% |
Short Selling Information
The latest short interest is 19.61M, so 11.49% of the outstanding shares have been sold short.
| Short Interest | 19.61M |
| Short % of Shares Out | 11.49% |
| Short % of Float | 15.71% |
| Short Ratio (days to cover) | 5.25 |
Valuation Ratios
The PE ratio is -1.58 and the forward PE ratio is -1.21.
| PE Ratio | -1.58 |
| Forward PE | -1.21 |
| PS Ratio | 1.42 |
| Forward PS | 5.3 |
| PB Ratio | -4 |
| P/FCF Ratio | -1.43 |
| PEG Ratio | n/a |
Enterprise Valuation
Seres Therapeutics Inc. has an Enterprise Value (EV) of 265.18M.
| EV / Earnings | -2.33 |
| EV / Sales | 2.1 |
| EV / EBITDA | -2.81 |
| EV / EBIT | -2.46 |
| EV / FCF | -2.12 |
Financial Position
The company has a current ratio of 1.78, with a Debt / Equity ratio of -2.26.
| Current Ratio | 1.78 |
| Quick Ratio | 1.48 |
| Debt / Equity | -2.26 |
| Total Debt / Capitalization | 179.13 |
| Cash Flow / Debt | -1.16 |
| Interest Coverage | -8.2 |
Financial Efficiency
Return on equity (ROE) is 2.54% and return on capital (ROIC) is -63.87%.
| Return on Equity (ROE) | 2.54% |
| Return on Assets (ROA) | -0.32% |
| Return on Capital (ROIC) | -63.87% |
| Revenue Per Employee | 542.17K |
| Profits Per Employee | -488.09K |
| Employee Count | 233 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 0.02 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -37.4% in the last 52 weeks. The beta is 2.05, so Seres Therapeutics 's price volatility has been higher than the market average.
| Beta | 2.05 |
| 52-Week Price Change | -37.4% |
| 50-Day Moving Average | 0.82 |
| 200-Day Moving Average | 0.89 |
| Relative Strength Index (RSI) | 38.83 |
| Average Volume (20 Days) | 2.49M |
Income Statement
In the last 12 months, Seres Therapeutics had revenue of 126.33M and earned -113.72M in profits. Earnings per share was -0.89.
| Revenue | 126.33M |
| Gross Profit | 125.62M |
| Operating Income | -107.98M |
| Net Income | -113.72M |
| EBITDA | -94.31M |
| EBIT | -107.98M |
| Earnings Per Share (EPS) | -0.89 |
Balance Sheet
The company has 127.97M in cash and 213.94M in debt, giving a net cash position of -85.97M.
| Cash & Cash Equivalents | 127.97M |
| Total Debt | 213.94M |
| Net Cash | -85.97M |
| Retained Earnings | -978.24M |
| Total Assets | 178.74M |
| Working Capital | 8.10M |
Cash Flow
In the last 12 months, operating cash flow was -117.35M and capital expenditures -7.97M, giving a free cash flow of -125.33M.
| Operating Cash Flow | -117.35M |
| Capital Expenditures | -7.97M |
| Free Cash Flow | -125.33M |
| FCF Per Share | -0.98 |
Margins
Gross margin is 99.44%, with operating and profit margins of -85.48% and -90.02%.
| Gross Margin | 99.44% |
| Operating Margin | -85.48% |
| Pretax Margin | -90.02% |
| Profit Margin | -90.02% |
| EBITDA Margin | -74.65% |
| EBIT Margin | -85.48% |
| FCF Margin | -99.21% |
Dividends & Yields
MCRB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -115.58% |
| FCF Yield | -95.18% |
Analyst Forecast
The average price target for MCRB is $5.62, which is 629.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.62 |
| Price Target Difference | 629.9% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -9.71 |
| Piotroski F-Score | 2 |